ImmunoQure & Servier Enter Partnership

ImmunoQure and Servier announced the establishment of a Worldwide, exclusive partnership for the development of a therapeutic autoantibody neutralizing interferon-alpha.

The companies will work collaboratively to advance ImmunoQure’s therapeutic human Interferon-alpha autoantibody through preclinical development and into the clinic, where Servier will assume all responsibilities for its development as therapeutic to treat diseases driven by elevated levels of interferon-alpha, with emphasis on systemic lupus erythemathosus and Sjögren’s syndrome. Under the terms of the agreement, Servier will provide ImmunoQure with an upfront payment and milestones amounting up to 164 million euros as well as royalties on net sales.

“We are very excited to advance our autoantibody into the clinic with Servier,” stated Professor Adrian Hayday, co-founder of ImmunoQure. “This is the next stage of our scientific strategy, for which Servier is an ideal partner, having demonstrated their expertise in developing high-potential therapeutics for the treatment of inflammatory diseases. Our partnership has the potential to help large numbers of patients in several disease indications, and – very importantly – can directly aid APECED/APS1 patients by facilitating our greater understanding of their condition, and by demonstrating our capability to move from basic research investigations to clinical development,”